Motoneuron survival is enhanced in the absence of neuromuscular junction formation in embryos.
Approximately half of the motoneurons produced during development die before birth or shortly after birth. Although it is believed that survival depends on a restricted supply of a trophic sustenance produced by the synaptic target tissue (i.e., muscle), it is unclear whether synapse formation per se is involved in motoneuron survival. To address this issue, we counted cranial motoneurons in a set of mutant mice in which formation of neuromuscular junctions is dramatically impaired (i.e., null mutants for agrin, nerve-derived agrin, rapsyn, and MuSK). We demonstrate that in the absence of synaptogenesis, there is an 18-34% increase in motoneuron survival in the facial, trochlear, trigeminal motor, and hypoglossal nuclei; the highest survival occurred in the MuSK-deficient animals in which synapse formation is most severely compromised. There was no change in the size of the mutant motoneurons as compared with control animals, and the morphology of the mutant motoneurons appeared normal. We postulate that the increased axonal branching observed in these mutants leads to a facilitated "access" of the motoneurons to muscle-derived trophic factors at sites other than synapses or that inactivity increases the production of such factors. Finally, we examined motoneurons in double mutants of CNTFRalpha(-/-) (in which there is a partial loss of motoneurons) and MuSK(-/-) (in which there is an increased survival of motoneurons). The motoneuron numbers in the double mutants parallel those of the single MuSK-deficient mice, indicating that synapse disruption can even overcome the deleterious effect of CNTFRalpha ablation.
Terrado
J
J
Division of Clinical Neuromuscular Research and Department of Anesthesiology, Pharmacology and Surgical Intensive Care, Faculty of Medicine, Centre Médical Universitaire, 1211 Geneva 4, Switzerland.
Burgess
R W
RW
DeChiara
T
T
Yancopoulos
G
G
Sanes
J R
JR
Kato
A C
AC
D018171:Agrin / Q000172:deficiency / Q000235:genetics; D000818:Animals; D000831:Animals, Newborn; D001369:Axons / Q000473:pathology; D002452:Cell Count; D002470:Cell Survival / Q000235:genetics; D003391:Cranial Nerves / Q000166:cytology / Q000196:embryology; D051379:Mice; D008817:Mice, Mutant Strains; D009046:Motor Neurons / Q000166:cytology / Q000378:metabolism*; D009124:Muscle Proteins / Q000172:deficiency / Q000235:genetics; D009469:Neuromuscular Junction / Q000196:embryology / Q000235:genetics / Q000473:pathology*; D020511:Neuromuscular Junction Diseases / Q000196:embryology / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D020033:Protein Isoforms / Q000172:deficiency / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000172:deficiency / Q000235:genetics; D020801:Receptor, Ciliary Neurotrophic Factor / Q000172:deficiency / Q000235:genetics; D011950:Receptors, Cholinergic
D018171:Agrin; D009124:Muscle Proteins; D020033:Protein Isoforms; D020801:Receptor, Ciliary Neurotrophic Factor; D011950:Receptors, Cholinergic; C051609:peripheral membrane protein 43K; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases